• Explore /
  • Poster
  • / Alkaline phosphatase (ALP) decline and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the REASSURE study.

Alkaline phosphatase (ALP) decline and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the REASSURE study.

Abstract Video & Slides Poster

Authors

Nicholas James

Nicholas D. James

The Institute of Cancer Research, London, United Kingdom

Nicholas D. James , Daniel Heinrich , Elena Castro , Saby George , Daniel Y. Song , Sabina Dizdarevic , Sergio Baldari , Markus Essler , Igle Jan de Jong , Secondo Lastoria , Peter G. Hammerer , Jeffrey Meltzer , Per Sandstrom , Frank Verholen , Bertrand F. Tombal , Joe M. O'Sullivan , A. Oliver Sartor

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5041)

DOI

10.1200/JCO.2022.40.16_suppl.5041

Abstract #

5041

Poster Bd #

225

Abstract Disclosures

Similar Posters

First Author: Celestia S. Higano

First Author: Celestia S. Higano

First Author: Esmail M. Al-Ezzi

First Author: Lauren Christine Harshman